Sort   by:  
 Page size 
UnknownCAR-T cells targeting HLA-G as potent therapeutic strategy for EGFR-mutated and overexpressed oral cancer.
Not available
S-EPMC9978640 | biostudies-literature
ProteomicsThe changes in HNSCC cell lines (e.g., CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main acetylation sites in resistance cell lines. In this study, it was found that the acetylation of STAT1 might hinder the downstream signaling of IFN-γ
Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We used LC-MS/MS to compare the acetylation sites in wild-type and resistant cells. We proposed that the acetylati...
ORGANISM(S): Homo sapiens (Human) 
2025-12-29 | PXD054332 | Pride
Human Lc-msms Hnscc Cetuximab resistance Acetylation 
ProteomicsThe changes in HNSCC cell lines (e.g., OECM1) when treated with Cetuximab (500 ug/ml) at different passages. We used LC-MS/MS to identify the main target pathway. These findings could significantly enhance our evidence.
Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We collected serial passages of cetuximab resistance HNSCC cell lines to perform LC-MS/MS. We identified the IFN p...
ORGANISM(S): Homo sapiens (Human) 
2025-12-29 | PXD054113 | Pride
Human Lc-msms Hnscc Cetuximab 
ProteomicsThe changes in cetuximab resistant HNSCC cell lines (e.g., OECM1-cetuximabR and CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main phosphorylation sites in resistance cell lines.
Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We used LC-MS/MS to compare the phosphorylation sites in wild-type and resistant cells. We proposed that the phosp...
ORGANISM(S): Homo sapiens (Human) 
2025-12-29 | PXD054186 | Pride
Human Lc-msms Hnscc Cetuximab resistance Phosphorylation 
UnknownPrognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen.
Not available
S-EPMC11452986 | biostudies-literature
GenomicsGenome wide association study of leprosy in Chinese population

Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae). Due to M. leprae's narrow host range and an inability to be cultured in vitro, the biological investigation of this disease has been difficult. Host genetic factors have been ...

phs000217.v1.p1 | EGA
UnknownTherapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy.
Not available
S-EPMC12711663 | biostudies-literature
ProteomicsUtilization of cross-linking mass spectrometry (XL-MS) for structural analysis of the ApoD-CD36 protein interaction
Structural analysis of the ApoD-CD36 complex by XL-MS.
ORGANISM(S): Homo Sapiens 
2025-11-20 | PXD070975 |
ProteomicsLiquid chromatography-mass spectrometry (LC-MS) for comparative proteomic analysis of human brain, lung, and kidney mural cells
We isolated PDGFRβ+ mural cells from tumor-adjacent normal human brain, lung, and kidney tissues. After lysis, we used LC-MS to profile differentially expressed proteins across these three cell types.
ORGANISM(S): Homo Sapiens 
2025-11-20 | PXD071101 |
ProteomicsLiquid chromatography-mass spectrometry (LC-MS) analysis of proteins co-immunoprecipitated with ApoD from endothelial-pericyte co-culture lysates
Liquid chromatography-mass spectrometry (LC-MS) analysis of the anti-ApoD immunoprecipitate.
ORGANISM(S): Homo Sapiens 
2025-11-20 | PXD071099 |
Sort   by:  
 Page size